Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

6 healthcare stocks Argus considers 'gems'

EditorRachael Rajan
Published 09/11/2023, 01:29 PM
Updated 09/11/2023, 01:30 PM
© Reuters.  6 healthcare stocks Argus considers 'gems'
LLY
-
MRK
-
ISRG
-
BIIB
-
MCK
-
CTLT
-

Argus now sees some possible gems in the healthcare sector, the firm's analysts said in a recent research note.

While overall, the firm has a Market-Weight rating on the sector, Argus noted that the category is broad and has underperformed the S&P 500 year-to-date.

As a result, they believe investors have an opportunity to "pick up some consistently steady companies, with big brands, and solid financials." The "science-focused" and innovative stocks the firm believes could be gems are:

Intuitive Surgical (NASDAQ:ISRG) is a stock the firm likes in the MedTech sector, describing it as an "industry leader in minimally-invasive robotics-assisted surgery."

"The da Vinci robotics system has head-start advantage and technical innovations, resulting in large installed base of systems in U.S. and overseas markets," the firm explained.

Argus pointed to Catalent (NYSE:CTLT) in life sciences, noting its transition from COVID-19 vaccines to focusing on developing and commercializing advanced biologics and gene therapies, including weight-loss drugs, Muscular Dystrophy, and others.

Meanwhile, the firm stated that McKesson (NYSE:MCK), in pharmaceutical distribution, is one of the largest pharmaceutical distributors in the U.S., pointing to its platform to add services and technology to customers.

Biotechnology firm Biogen (NASDAQ:BIIB), which is down 16% in the last three months, is another stock that Argus believes is a "gem." The company develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases, including Alzheimer's.

One of the largest pharmaceutical companies in the world, Eli Lilly & Co. (NYSE:LLY), is one of Argus's favored stocks, with the firm noting the company's weight-loss drug development and its "promising treatment for Alzheimer's disease."

Finally, another pharmaceutical firm, Merck & Company Inc (NYSE:MRK), is Argus's final pick in healthcare, with the firm stating the company has a "number of successful products on the market targeting various cancers and diabetes, as well as animal health products and vaccines for a range of diseases."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.